Table 4 Top 3 most common CERA dosage/administration schedules when switching from erythropoietin-stimulating agent
| ND | HD | PD | |
|---|---|---|---|
| 1 |
EPO < 4500 IU/wk. → 100 μg/4 wks (65/286; 22.72%) |
EPO ≥4500 IU/wk. → 150 μg/4 wks (153/664; 23.04%) |
EPO < 4500 IU/wk. → 100 μg/4 wks (5/32; 15.62%) |
| 2 |
EPO < 4500 IU/wk. → 50 μg/4 wks (31/286; 10.83%) |
EPO ≥4500 IU/wk. → 100 μg/4 wks (124/664; 18.67%) |
EPO ≥4500 IU/wk. → 100 μg/4 wks (5/32; 15.62%) |
| 3 |
EPO ≥4500 IU/wk. → 150 μg/4 wks (29/286; 10.13%) |
EPO < 4500 IU/wk. → 100 μg/4 wks (67/664; 10.09%) |
Others → 100 μg/4 wks (5/32; 15.62%) |
| 1 |
DA ≥30 and < 40 (μg/wk) → 100 μg/4 wks (55/523; 10.51%) |
DA ≥40 and < 60 (μg/wk) → 150 μg/4 wks (59/620; 9.51%) |
DA ≥30 and < 40 (μg/wk) → 150 μg/4 wks (28/231; 12.12%) |
| 2 |
DA ≥15 and < 20 (μg/wk) → 100 μg/4 wks (51/523; 9.75%) |
DA ≥20 and < 30 (μg/wk) → 100 μg/4 wks (45/620; 7.25%) |
DA ≥30 and < 40 (μg/wk) → 100 μg/4 wks (21/231; 9.09%) |
| 3 |
DA ≥15 and < 20 (μg/wk) → 50 μg/4 wks (49/523; 9.36%) |
DA ≥60 (μg/wk) → 200 μg/4 wks (44/620; 7.09%) |
DA ≥15 and < 20 (μg/wk) → 100 μg/4 wks (14/231; 6.06%) |